永泰生物-B(06978.HK)成立並作為有限合夥人投資細胞免疫治療專項產業基金
格隆匯 2 月 25日丨永泰生物-B(06978.HK)發佈公吿,公司間接全資附屬公司北京永泰與天津金新、紹興濱海投資基金及天津天鍵訂立有限合夥協議,內容有關成立產業基金。基金的承諾出資總額為人民幣10億元,北京永泰作為有限合夥人於產業基金的資本承擔總額為人民幣5000萬元。
2021年2月24日,公司透過北京永泰與管理委員會訂立合作框架協議,旨在通過北京永泰的引薦促進紹興濱海新區生物醫療產業的發展,從而參與華東細胞產業園項目,包括(其中包括)建議為華東地區設立EAL®研發與生產中心、建議與中國高校及科研機構聯合成立院士工作站、建議有關項目的土地開發及建議成立專項產業基金,目標是投資於(其中包括)細胞免疫治療上下游產業鏈。
公吿表示,集團一直就其擬參與建議華東細胞產業園項目與管理委員會進行討論。預期華東細胞產業園為專注於細胞免疫治療及精準醫療產業鏈的產業園,管理委員會可在此實施多項支援措施。預期參與項目符合當地政策,即於中國華東地區主要省份浙江省紹興市紹興濱海新區發展生物醫療產業。
在此背景下,董事會認為,成立產業基金將進一步加強集團與管理委員會之間的聯繫,從而為探索潛在商機及╱或與管理委員會合作提供便利,促進集團產品於中國的商業化。根據有限合夥協議的條款,預期產業基金將投資於紹興濱海新區內的企業,可能包含與公司核心產品(即EAL®)開發有關產業鏈業務的企業。董事會認為,產業基金的再投資計劃可促進公司核心產品的商業化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.